Apollomics Inc. - Class A Ordinary Shares (APLM)
APLM moved a median of 0.00% 30 minutes after news, and -1.15% by the close. How APLM actually reacts to news — the realized, point-in-time move the market made, measured across 132 labeled events over the last three years with zero look-ahead.
APLM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 95 |
| 30-min | 0.00% | 47% | 110 |
| 60-min | -1.51% | 40% | 123 |
| to close | -1.15% | 36% | 127 |
| Middle 50% of APLM reactions | -2.80% to +1.81% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 132 |
Half of all Apollomics Inc. - Class A Ordinary Shares news events land between -2.80% and +1.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when APLM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APLM's baseline. Nothing else.
Recent APLM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form D Apollomics Inc. | SEC filing · Form D | SEC EDGAR | -3.85% | -1.38% | |
| Form 6-K Apollomics Inc. For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -7.08% | |
| Apollomics Announces $10 Million Private Placement Transaction | Press release | GlobeNewswire | +0.00% | -7.08% | |
| Form 6-K Apollomics Inc. For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | — | +4.73% | |
| Form 6-K Apollomics Inc. For: Jul 14 | SEC filing · Form 6-K | SEC EDGAR | — | +4.67% | |
| Apollomics Regains Full Compliance with Nasdaq Listing Requirements | Press release | GlobeNewswire | — | -24.61% | |
| Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia | Press release | GlobeNewswire | — | +6.54% | |
| Form 6-K Apollomics Inc. For: Jun 24 | SEC filing · Form 6-K | SEC EDGAR | — | +6.54% | |
| Form EFFECT Apollomics Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | -1.56% | |
| Form F-3/A Apollomics Inc. | SEC filing · Form F-3 | SEC EDGAR | — | — | |
| Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress | Press release | GlobeNewswire | +0.80% | -0.15% | |
| Form 6-K Apollomics Inc. For: Apr 27 | SEC filing · Form 6-K | SEC EDGAR | +0.80% | -0.15% | |
| Form 20-F Apollomics Inc. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.80% | -0.15% | |
| Apollomics Inc. Announces $2.0 Million Bridge Financing | Press release | GlobeNewswire | — | -5.64% | |
| Form 6-K Apollomics Inc. For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form F-3 Apollomics Inc. | SEC filing · Form F-3 | SEC EDGAR | — | +0.00% | |
| Form S-8 Apollomics Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.69% | |
| Apollomics Reports First Half 2025 Financial Results | Press release | GlobeNewswire | +0.00% | -8.69% | |
| Form 6-K Apollomics Inc. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -8.69% | |
| Form 6-K Apollomics Inc. For: Dec 11 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.75% | |
| Apollomics Announces Settlement of Cayman Litigation | Press release | GlobeNewswire | +0.00% | -16.57% | |
| Form 6-K Apollomics Inc. For: Nov 19 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -16.57% | |
| Form 6-K Apollomics Inc. For: Nov 17 | SEC filing · Form 6-K | SEC EDGAR | +10.22% | +4.74% | |
| Apollomics Announces Changes to its Board of Directors and Composition of Committees | Press release | GlobeNewswire | +0.00% | -13.29% | |
| Form 6-K Apollomics Inc. For: Oct 21 | SEC filing · Form 6-K | SEC EDGAR | — | -16.87% | |
| Form 6-K Apollomics Inc. For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +59.90% | |
| Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation | Press release | GlobeNewswire | +1.69% | -2.75% | |
| Form 6-K Apollomics Inc. For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Apollomics, Inc. Company Operational Continuity Update | Press release | GlobeNewswire | — | — | |
| Form 6-K Apollomics Inc. For: Sep 25 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K Apollomics Inc. For: Sep 05 | SEC filing · Form 6-K | SEC EDGAR | +0.55% | -4.80% | |
| Form 6-K Apollomics Inc. For: Sep 03 | SEC filing · Form 6-K | SEC EDGAR | +9.03% | +30.17% | |
| Form 6-K Apollomics Inc. For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | +2.00% | -18.42% | |
| Form 6-K Apollomics Inc. For: Jul 25 | SEC filing · Form 6-K | SEC EDGAR | -0.16% | -0.80% | |
| Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress | Press release | GlobeNewswire | -0.91% | -8.81% | |
| Form 20-F Apollomics Inc. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.91% | -8.81% | |
| Form 6-K Apollomics Inc. For: Apr 03 | SEC filing · Form 6-K | SEC EDGAR | -0.91% | -8.81% | |
| Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib | Press release | GlobeNewswire | +0.27% | -17.44% | |
| Form 6-K Apollomics Inc. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | -17.44% | |
| Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Press release | GlobeNewswire | -1.62% | +12.72% | |
| Form 6-K Apollomics Inc. For: Dec 20 | SEC filing · Form 6-K | SEC EDGAR | -1.62% | +12.72% | |
| Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement | Press release | GlobeNewswire | — | +5.48% | |
| Form 6-K Apollomics Inc. For: Dec 10 | SEC filing · Form 6-K | SEC EDGAR | — | +5.48% | |
| Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split | Press release | GlobeNewswire | -0.08% | -15.83% | |
| Form 6-K Apollomics Inc. For: Nov 14 | SEC filing · Form 6-K | SEC EDGAR | -2.96% | -8.32% | |
| Form 6-K Apollomics Inc. For: Nov 01 | SEC filing · Form 6-K | SEC EDGAR | +0.76% | -4.20% | |
| Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 | Press release | GlobeNewswire | +2.24% | +0.67% | |
| Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Press release | GlobeNewswire | +1.32% | +3.71% | |
| Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress | Press release | GlobeNewswire | -3.49% | -0.52% | |
| Form 6-K Apollomics Inc. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.67% | +9.63% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APLM section they belong to.
Where else APLM is measured.
APLM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Apollomics Inc. - Class A Ordinary Shares's median reaction calculated?
Every labeled APLM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 132 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of APLM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APLM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.